ATE537454T1 - Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15 - Google Patents

Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15

Info

Publication number
ATE537454T1
ATE537454T1 AT07108852T AT07108852T ATE537454T1 AT E537454 T1 ATE537454 T1 AT E537454T1 AT 07108852 T AT07108852 T AT 07108852T AT 07108852 T AT07108852 T AT 07108852T AT E537454 T1 ATE537454 T1 AT E537454T1
Authority
AT
Austria
Prior art keywords
gdf
heart failure
atrial fibrillation
patients
assessing heart
Prior art date
Application number
AT07108852T
Other languages
English (en)
Inventor
Georg Hess
Andrea Horsch
Hendrik Huedig
Dietmar Zdunek
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE537454T1 publication Critical patent/ATE537454T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT07108852T 2007-05-24 2007-05-24 Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15 ATE537454T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07108852A EP1995596B1 (de) 2007-05-24 2007-05-24 Verfahren zum Beurteilen von Herzinsuffizienz bei Patienten mit Vorhofflimmern mittels GDF-15

Publications (1)

Publication Number Publication Date
ATE537454T1 true ATE537454T1 (de) 2011-12-15

Family

ID=38190863

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07108852T ATE537454T1 (de) 2007-05-24 2007-05-24 Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15

Country Status (6)

Country Link
US (1) US7955854B2 (de)
EP (1) EP1995596B1 (de)
JP (1) JP5015318B2 (de)
AT (1) ATE537454T1 (de)
ES (1) ES2379104T3 (de)
WO (1) WO2008142110A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027514A1 (en) * 2007-08-30 2009-03-05 Roche Diagnostics Gmbh Means and methods for the discrimination of gdf-15 elevation related or unrelated to cardiac disorders
EP2227696A1 (de) * 2008-01-08 2010-09-15 Roche Diagnostics GmbH Mittel und verfahren zur risikobewertung von patienten bei der einlieferung in die notfallstation auf gdf-15-basis
WO2011012268A1 (en) 2009-07-27 2011-02-03 Roche Diagnostics Gmbh Use of mimecan in the assessment of heart failure
CA2776978A1 (en) * 2009-10-21 2011-04-28 Pronota N.V. Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof
EP2439535A1 (de) * 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnose von Herzerkrankungen im Zusammenhang mit Diabetes und GDF-15 und Troponin als Prädiktor für die Entwicklung von Diabetes mellitus Typ 2
KR101230088B1 (ko) 2010-11-24 2013-02-05 연세대학교 산학협력단 심방세동의 예후 예측 방법
BR112016028833A2 (pt) * 2014-06-13 2017-08-22 Novartis Ag uso de serelaxinaa para reduzir gdf-15
CN108700573B (zh) 2016-02-29 2021-06-11 公立大学法人横滨市立大学 检测去势抵抗性前列腺癌的方法和检测试剂
BR112018073214A2 (pt) * 2016-06-17 2019-04-16 F. Hoffmann-La Roche Ag métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador
WO2018167447A1 (en) 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
JP7127422B2 (ja) 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
CN113167799B (zh) * 2018-07-31 2025-01-10 豪夫迈·罗氏有限公司 循环DKK3(Dickkopf相关蛋白3)在心房颤动评定中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2567738C (en) * 2004-06-15 2010-12-21 F. Hoffmann-La Roche Ag The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication
JP4828550B2 (ja) * 2005-02-17 2011-11-30 エフ．ホフマン−ラ ロシュ アーゲー 心機能障害を診断するためのＮＴ−ｐｒｏＡＮＰ／ＮＴ−ｐｒｏＢＮＰ比の使用
WO2008015254A2 (en) * 2006-08-04 2008-02-07 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
WO2009027514A1 (en) * 2007-08-30 2009-03-05 Roche Diagnostics Gmbh Means and methods for the discrimination of gdf-15 elevation related or unrelated to cardiac disorders

Also Published As

Publication number Publication date
US7955854B2 (en) 2011-06-07
US20100159608A1 (en) 2010-06-24
EP1995596A1 (de) 2008-11-26
ES2379104T3 (es) 2012-04-20
JP5015318B2 (ja) 2012-08-29
EP1995596B1 (de) 2011-12-14
JP2010528275A (ja) 2010-08-19
WO2008142110A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
EP4278366A4 (de) Gesundheitstest- und diagnoseplattform
Bates et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines
DE602006014535D1 (de) Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen
JP2010517618A5 (de)
ATE533061T1 (de) Verfahren zur diagnose bakterieller infektionen
JP2008272477A5 (de)
EP2117422A4 (de) Verfahren und system zur bestimmung eines zerebrovaskulären autoregulationszustands eines patienten
JP2012529655A5 (de)
WO2009092386A8 (en) A new method to measure and characterize microvesicles in the human body fluids
WO2008095492A3 (en) A method for diagnosing atherosclerotic plaques by measurement of cd36
GB201021399D0 (en) Oligonucleotide probe set and methods of microbiota profiling
WO2009047283A3 (en) Means and methods for monitoring myocardial infarction and its treatment
JP2018536170A5 (de)
AR076041A1 (es) Biomarcadores de proteina para el diagnostico de enfermedades de tejido blando y como objetivos terapeuticos para intervenciones de cuidado oral
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
WO2008101154A3 (en) Immunotherapy for immune suppressed patients
JP5006070B2 (ja) ストレス強度演算方法、及びストレス強度演算装置
ATE477329T1 (de) Verfahren zur detektion der in-vivo-aktivität von neurotrypsin, verwendung des verfahrens und verwendung des c-terminal 22-kda-fragments als biomarker bei der diagnose und überwachung von störungen im zusammenhang mit neurotrypsin
JP2012533066A5 (de)
WO2008125681A8 (en) Means and methods for assessing the risk of a cardiac intervention in patients suffering from a stable coronary heart disease based on gdf-15
RU2008147047A (ru) Способ диагностики хронического генерализованного пародонтита с агрессивным течением
DE602007013615D1 (de) Verfahren und kits zur diagnose von multipler sklerose bei wahrscheinlichen multiple-sklerose-patienten
DE602005023973D1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
RU2008131766A (ru) Способ реабилитации опорно-двигательного аппарата